This review concluded that compared with placebo, nimodipine can improve clinical outcomes and reduce the occurrence of symptomatic cerebral vasospasm and delayed neurological function deficits as well as cerebral infarction. The authors' conclusion reflects the evidence presented but should be interpreted with caution in view of limitations of reporting in several aspects in the review process and methods.
Study selection
Randomised controlled trials (RCTs) that evaluated nimodipine versus placebo in the prevention of cerebral vasospasm in patients with aneurysmal subarachnoid haemorrhage were eligible for inclusion. Eligible studies had to report outcomes of death, delayed cerebral ischaemia and adverse effects.
All the included studies recruited patients with aneurysmal subarachnoid haemorrhage caused by a ruptured aneurysm. Most studies used oral administration of drugs. Some studies employed intravenous infusion or intravenous infusion followed by oral administration of drugs. Nimodipine dosage and treatment duration varied between the included studies. Where reported, patient age ranged from 15 to 79 years.
The authors did not state how many reviewers assessed studies for inclusion.
Assessment of study quality
Study quality was assessed using the five-point Jadad scale of randomisation, blinding, withdrawals and drop-outs. It appeared that allocation concealment was used as an additional criterion. The authors stated that studies that scored at least 3 were classed as high quality. The maximum possible quality score was unclear because of the inclusion of the additional criterion.
Two reviewers independently performed quality assessment. Uncertainties were resolved through discussion.
Data extraction
Data were extracted on event rates and used to calculate odds ratios (ORs) with 95% confidence intervals (CIs). Data were extracted on the basis of an intention-to-treat approach.
Two reviewers independently performed data extraction.
Methods of synthesis
The studies were combined in a meta-analysis. Pooled odds ratios with 95% CIs were calculated. The authors stated that statistical heterogeneity was evaluated but it was unclear which statistic was used. A random-effects model was used for the meta-analysis where there was significant heterogeneity and otherwise a fixed-effect model was employed. Stratification analyses were performed on the basis of cerebral vasospasm cases. Where the result was statistically significant, publication bias was assessed by calculating the fail safe number.
